slides · global inventory
Present Solution
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 24,547
Current window 16,441-16,470
Pages 819
Rows per page 30
Slide function
16,441-16,470 of 24,547
30
The slide uses a structured column layout to map specific technical capabilities to strategic business outcomes.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
31
Uses a timeline framework to contrast traditional drug development timelines with Absci's accelerated approach.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
43
The slide uses a process flow diagram to illustrate the AI-driven drug development pipeline.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
65
The chart uses a logarithmic scale to demonstrate the divergence between sequential CPU performance and accelerated computing/AI performance.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
66
The chart uses a logarithmic scale on the Y-axis to show exponential growth differences.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
68
The slide uses a process flow diagram to explain the technical workflow of the company's core technology.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
71
The slide uses a process flow diagram to map specific AI models to stages of drug discovery.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
78
The slide uses a process flow framework to show the integration of AI across the drug development lifecycle.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
79
The slide outlines a proprietary workflow combining AI-driven design with experimental validation.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
84
The slide uses a process flow framework to show the progression from target discovery to optimized antibodies.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
87
The slide uses a two-step process flow (1 and 2) to explain the technical methodology of their AI-driven drug discovery platform.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
91
The slide uses a consistent visual metaphor of a Y-shaped antibody binding to three distinct targets in each of the three columns.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
99
The chart is a dot plot showing affinity (KD) vs edit distance from parent binder. The benchmark is a horizontal dashed line.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
100
The slide uses a side-by-side comparison structure to detail the value proposition of two specific drug candidates.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
101
The slide illustrates a dual-pathway process leading to a unified AI-driven optimization step.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
103
The slide outlines a proprietary R&D workflow for antibody discovery.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
106
The chart shows a dose-dependent increase in absorbance for ABS-301 compared to isotype controls, suggesting binding/inhibition activity.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
108
The chart uses a horizontal bar format to represent development progress against a timeline of stages (Target Eval to IND).Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
04
The slide uses a structured comparison layout to differentiate between individual programs and a combination strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
06
The slide uses a three-column layout to present distinct technological approaches.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
04
The slide uses a three-column layout to compare product candidates.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Situation & Context1 hit
06
The slide uses a three-column layout to present the company's core technological approaches.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Evidence & Proof1 hit
10
Includes structural biology visualization, dose-response curves, and a binding affinity table.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Evidence & Proof1 hit
21
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
22
The slide uses a funnel diagram to illustrate the selection process from initial discovery sets to final candidate properties.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
23
The slide uses two distinct chart types: a scatter plot for binding affinity and a dose-response curve for functional inhibition.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
28
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
29
The slide uses a biological process diagram to map drug targets to specific cellular mechanisms (T-cell trafficking, Colonic Fibrosis, Inflammatory cascade, Th17 maturation).Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit